Your browser doesn't support javascript.
loading
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
Jacobs, Jeremy W; Booth, Garrett S; Stephens, Laura D; Tormey, Christopher A; Adkins, Brian D.
Affiliation
  • Jacobs JW; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: jeremy.w.jacobs@vumc.org.
  • Booth GS; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Stephens LD; Department of Pathology, University of California San Diego, La Jolla, CA, USA.
  • Tormey CA; Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Adkins BD; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Lancet ; 404(10451): 433, 2024 Aug 03.
Article in En | MEDLINE | ID: mdl-39097393
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purpura, Thrombocytopenic, Idiopathic Limits: Humans Language: En Journal: Lancet Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purpura, Thrombocytopenic, Idiopathic Limits: Humans Language: En Journal: Lancet Year: 2024 Type: Article